Correction to “Letter to Editor in response to ‘Acute kidney injury in 18 cats after subcutaneous meloxicam and an update on non-steroidal anti-inflammatory drug usage in feline patients in Australia’”

Abstract

Goodwin G, Monteiro BP, Grimm K et al. Letter to Editor in response to “Acute kidney injury in 18 cats after subcutaneous meloxicam and an update on non-steroidal anti-inflammatory drug usage in feline patients in Australia”. Aust Vet J 2023;101:411–412. 10.1111/avj.13279

In the original Letter to the Editor, no conflict of interest statement from the authors was published. It was an oversight by the publisher not to have included it. The below conflict of interest statement outlines any perceived competing interests of the authors. We apologise for this error.

CONFLICTS OF INTEREST

At the time of writing, W.G. declares that she had received research support, consultancy fees and/or honoraria from Boehringer Ingelheim, Jurox Pty Ltd and Invetus Pty Ltd. These relationships have not inappropriately influenced the content of this manuscript, and all scientific judgments are her own. She authored the letter on behalf of the Veterinary Anaesthesia & Analgesia Chapter of the Australian and New Zealand College of Veterinary Scientists (ANZCVS), and all Chapter members were given the opportunity to provide comments on the letter prior to submission. P.S. has provided consultancy services to, and received honoraria from, Boehringer Ingelheim, Dechra, Elanco, Nexyon, Vetoquinol, Virbac and Zoetis. B.M. has provided consultancy services to and received honoraria from Boehringer Ingelheim, Elanco, Vetoquinol and Zoetis. B.M. and P.S. co-authored this letter while members of the WSAVA Pain Committee. At the time of writing, K.G. did not have any active consulting agreements in place with any group. He had done some education and speaking on behalf of Zoetis and Elanco in the years prior to that. K.G. co-authored the letter while president of the American College of Veterinary Anesthesia and Analgesia (ACVAA).